London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Of relevance also VIS LFT mamuafacure / availability is that Affimer production volume only. “reagent” that can be produced on volume to meet anticipated demand. Antibody production N/A.
GLA
I raised this because I was surprised that they were so specific calling it point of care test, but actually they are contracted to Medusa for consumer test.
Then rereading the blurb, they have definitely nailed their clours to the mast
Quote
- a saliva based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection,
They are focussed on their key markets.
Government Medical Advisors to make a statement at 11am followed by a Statement from the Prime Minister, do you think he will let the cat out of the bag referencing LFD rapid test ? Knowing what he knows facing huge criticism for not producing a decent track & trace and testing system. If it were me I would not be able to contain myself.
LSE has been down this morning. I actually enjoyed the silence. It gave us all a break from you.
MF - I think everyone is probably watching the slaughter on the rest of their portfolio unless one is all in on AVCT... I doubt you are all in... or at all in?
Wow this is the quietest I have seen this bb or any COVID stock you would not think we were in the eye of a second wave with COVID.
A bit of free advice to Al your meant to under promise and over deliver not the other way round ;-)
RK...& Could well save the current gov.s Bacon too...
Redreversion, do you think this means that the affimers will ignore the COVID RNA fragments that appear to be the problem behind false positive results in PCR testing?
I hope Alastair’s pièce de résistance for 28th is not this new website. Not why I invested in AVCT!
Had a little nose around the website and read the bios (again):
On Alistair's, I found it noteworthy that it states Avacta's first drug will be in the clinic in 2020 - previously there has been some ambiguity about 2020/2021...
From the updated website:
“Engineered specificity
Large binding surface obtained through two 9 amino acid loops enable Affimer® proteins to bind with high-Affinity and exquisite selectivity. In-vitro phage display selection allows for a tailored screening approach to discriminate between closely related targets.“
EXQUISITE SELECTIVITY!
cool
Well Yorkshirepragma, stage 1 is to get approvals and production and sales from BBI and Abingdon Health, that will be the perfect start. Orders and production ramp up is phase 2, although orders is about the most sure thing right now that we could imagine. They will sell every test they can make in the next 12 months at least. Be that 1 million or 1 billion!
BAMS, POC LFD and of course ELISA!
Avacta will be a globally significant player.
Successful supplies of tests will be key, S&S critical and speed of results will safe the NHS and every industry billions. Our tests are that important.
Cheers Rich
RK ....with tests on the increase for obvious reasons ( mass being the aim ) across the world
https://ourworldindata.org/coronavirus-testing#how-many-tests-are-performed-each-day
The only outstanding question is can production keep up....and Avactas M.Cap.too perhaps
GLA
Thanks !
Awight then!
You say Avacta I say Awacta
Let's call the whole thing off
It is good to see that Avacta are making sure they present all aspects of the business in totally professional way! It looks crisp and fresh and high quality. Given the world they operate in and the multiple partnerships they have already in progress and the potential moving forward. I am delighted with the totally professional look and crisp presentations!
Great work Avacta. https://avacta.com/
I expect a lot of move around over the next few weeks as the Covid19 situation is clearly heading in the wrong direction. Avacta are closer than ever to offering multiple testing opportunities for the masses and when they do then we can expect a valuation much, much higher than today.
Have a good week all! And no, I am not selling!!
Cheers, Rich
You might do better to word the request to not use awacta differently rather than just calling it juvenile.
It was once a bit of an in joke and harmless then, but given a potential influx of new investors it could devalue some of the great research and discussions here to those that might not have been around for the “in” joke and put them off from reading some of the good stuff here.
Some could also argue it is the tip of the iceberg as there is so much ramping and derampimg it is getting more and more difficult to sift through to find the gems. For the sake of trying to promote good research could we call the company Avacta, please? GLA
gmcc link still not working, trying this:
https://www.selectscience.net/editorial-articles/covid-19-testing-using-lateral-flow-assays-sensitive-rapid-easy-to-use?artID=52363
I agree!! Childish and immature. There are a couple on here that continually do it and it in no way serves to promote Avacta.
https://www.selectscience.net/editorial-articles/covid-19-testing-using-lateral-flow-assays-sensitive,-rapid,-easy-to-use-and-point-of-care/?artID=52363
Sorry Oops " 7 September 2020 " got inserted into AVCT quote .
Link did not work try again , apologies
https://www.selectscience.net/editorial-articles/covid-19-testing-using-lateral-flow-assays-sensitive,-rapid,-easy-to-use-and-point-of-care/?artID=52363ps
Hi TheAlchemyst AVCT in latest RNS do not mention POC .
Recent RNS dated 7 September 2020 https://www.lse.co.uk/rns/AVCT/avacta-to-launch-sars-cov-2-elisa-laboratory-test-uo6uhidvjlsnn2q.html
"Avacta remains focused on the much larger opportunity of the saliva-based coronavirus antigen rapid test that we are developing with Cytiva and which is now in the process of technology transfer to our manufacturing partners. The excellent analytical performance of the ELISA test is very encouraging with regards to the anticipated clinical performance of the rapid test and I look forwa7 September 2020rd to starting the clinical validation with the first pilot batch of rapid tests as soon as possible."
----------------------------
This science article mentions " point-of-care " in the heading and goes on to say "can be successfully performed without any help from a qualified healthcare professional." so a bit confusing ?
Heading "COVID-19 testing using lateral flow assays: sensitive, rapid, eas"y to use and point-of-care"
https://www.selectscience.net/editorial-articles/covid-19-testing-using-lateral-flow-assays-sensitive,-rapid,-easy-to-use-and-point-of-care/?artID=52363
"Portable point-of-care "
The design, application, and manufacturing of lateral flow tests offer numerous benefits compared to other immunoassays such as ELISA, especially during a global pandemic when time is of the essence. “Lateral flow tests are cost-effective,” says O’Brien. “They're cheap to manufacture at a large scale. They are also simple to use, offer results rapidly, and are portable.”
Hants
Just curious why do you still call the company Awacta I just cannot get past how juvenile and disrespectful it sounds as in the main you are a good quality poster